<DOC>
	<DOCNO>NCT01040715</DOCNO>
	<brief_summary>The objective trial demonstrate active immunization anti-TNFα kinoid ( TNF-K ) able induce polyclonal anti-TNFα antibody RA patient previously treat anti-TNFα mAb lose susceptibility therapy .</brief_summary>
	<brief_title>Immunogenicity Safety TNFa Kinoid Rheumatoid Arthritis With Secondary Resistance TNFa Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis RA accord revised 1987 criterion American College Rheumatology ( ACR ) ( Arnett 1988 ) since least six month prior first study product administration . Male female 18 70 year age time first immunization Active RA disease evidence Disease Activity Score 28 ( DAS 28 ) ≥ 3.2 . Current past treatment antiTNF antagonist ( infliximab , adalimumab , etanercept , certolizumab , golimumab ) . A washout period first administration study product least ten week since last administration certolizumab golimumab ; least eigth week since last administration infliximab ; least four week since last administration adalimumab etanercept History positive response define ACR20 DAS 28 decrease ≥ 1.2 investigator opinion previous TNFα antagonist treatment . Secondary treatment failure maximum one previous TNFα antagonist treatment define : Investigator opinion . OR DAS28 increase ≥ 0.6 last six month . OR Decrease European League Against Rheumatoid ( EULAR ) score . Written informed consent . Treatment nonbiological DMARDs within four week prior first study product administration . MTX allow provide administer table dosage &lt; ou = 20 mg/week since least 4 week . Treatment rheumatoid arthritis biological therapy TNFα antagonists time prior first study product administration . Administration high dos intraarticular corticosteroid treatment acute monoarthritis ( eg knee ) within 3 month prior first study product administration . High dose corticosteroid define &gt; 50 mg triamcinolone equivalent . History document severe bacterial infection within 28 day prior first immunization History primary resistance intolerance TNFα antagonist . History current congestive heart failure , control . Corticosteroids ( prednisone equivalent , &lt; ou = 10 mg per day ) allow administer stable dosage since lesat 4 week prior first immunization . Inhaled topical steroid allow . Known history tuberculosis ( TB ) . Suspicion TB chest Xrays screen within three month prior first administration study product . Suspicion latent active tuberculosis define : Positive Mantoux/Purified Protein Derivative ( PPD ) test ( &gt; ou = 5mm induration measure 48 72 hour intradermal injection tuberculin ) screening within 30 day prior first administration study product . and/or positive interferonγ ( IFN γ ) TB diagnostic test ( measure ELISpot method ) screening within three month prior first administration study product . Positive HIV , HCV HBV include HBsAg antiHBc antibody . Use investigational nonregistered product ( drug vaccine ) . Administration live vaccine within three month prior study entry Any confirm suspected immunosuppressive immunodeficient condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>anti-drug antibody</keyword>
	<keyword>Rheumatoid arthritis secondary loss efficacy anti-TNFa antagonist anti-drug antibody</keyword>
</DOC>